Dana D. Hu‐Lowe

机构：Sepragen Corporation (United States)

发表论文 82 篇 · 总被引 3953 次 · h-index 19

代表论文

Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC. (2025 · Journal of Clinical Oncology · 被引 3)
Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC. (2025 · Journal of Clinical Oncology · 被引 2)
39O A phase Ib/II update of ADG126 (an anti-CTLA-4 masking antibody) across different dosing regimens in combination with pembrolizumab in advanced/metastatic MSS CRC (2025 · ESMO Open · 被引 1)
744 Phase 1b/2, multicenter dose escalation and expansion study of muzastotug (ADG126, a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab in advanced/metastatic MSS CRC (2024 · Regular and Young Investigator Award Abstracts)
578P Increased therapeutic index of muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with pembrolizumab (pembro) enables significant clinical benefits and supports further clinical development in patients with metastatic MSS CRC (2024 · Annals of Oncology)
Abstract CT233: Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors (2023 · Cancer Research)